Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyCommunity Health Plan Washington gene therapy Cove…
    Ask Trek AI about this page
    CurrentCommunity Health Plan WashingtonPolicy 82.80.40-1

    Hematopoietic Agents – Sickle Cell Disease Cell and Gene Therapies

    Customize your policy alerts

    Sign up for Community Health Plan Washington Policy 82.80.40-1 alerts

    Get alerted when Policy 82.80.40-1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, dosing/quantity limits, coding, and authorization rules for the two one-time gene therapies (Casgevy and Lyfgenia) for sickle cell disease with recurrent vaso-occlusive crises/events for Apple Health (Community Health Plan Washington). Also requires treatment centers to be CIBMTR-enrolled per CMS CMMI model.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyHematopoietic Agents – Sickle Cell Disease Cell and Gene Therapies
    Policy CodePolicy 82.80.40-1
    Change TypeNew policy created
    Effective DateJan 1, 2026
    Last ReviewNov 19, 2025
    Next Review DateN/A
    Key ActionRequests for Exagamglogene autotemcel or Lovotibeglogene autotemcel must meet the clinical criteria and non-preferred new-to-market agents are subject to prior authorization requiring inadequate response/intolerance to preferred agents.
    SourceLink
    POLICY UPDATE CHANGES

    New policy created

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Gene therapies covered under policy
    1One-time dose requirement
    >=12Minimum patient age (years)
    3.0×10^6Minimum CD34+ cells/kg

    Coverage Summary

    Coverage stance: covered_with_criteria for two one-time gene therapies: Exagamglogene autotemcel (Casgevy) and Lovotibeglogene autotemcel (Lyfgenia). Policy defines medical necessity criteria, dosing/quantity limits, coding, and authorization rules for these therapies and specifies that both are single, one-time doses.

    Scope summary: Defines medical necessity criteria, dosing/quantity limits, coding, and authorization rules for the two one-time gene therapies (Casgevy and Lyfgenia) for sickle cell disease with recurrent vaso-occlusive crises/events for Apple Health (Community Health Plan Washington). Treatment centers must be enrolled in the CIBMTR registry per the CMS CMMI Cell and Gene Therapy Access Model before administering gene therapies to Apple Health clients.

    Policy number: 82.80.40-1. Effective date: 01/01/2026. Status: CURRENT.

    Minimum CD34+ cell dose threshold: minimum dose of 3.0 × 10^6 CD34+ cells/kg.

    Key thresholds
    Age requirement>= 12 years at expected time of gene therapy administration
    Casgevy VOC frequency>= 2 VOCs per year in prior 24 months (provider attestation)
    Lyfgenia VOE frequency>= 4 VOEs in prior 24 months (provider attestation)
    Minimum CD34+ cells/kgminimum dose of 3.0 × 10^6 CD34+ cells/kg
    One-time dose requirementSingle, one-time gene therapy dose; reauthorization not appropriate unless prior auth expired and therapy not received
    Number of gene therapies covered2

    Exagamglogene autotemcel (Casgevy) - Initial Therapy (Medical Necessity)

    Exagamglogene autotemcel (Casgevy) - Initial Therapy (Medical Necessity)

    Covered when ALL of the following are met:

    ALL of the following

    • Patient is 12 years of age or older at expected time of gene therapy administration
    • Prescribed by, or in consultation with a board-certified hematologist with SCD experience at a qualified treatment center

      Treatment centers must be enrolled in CIBMTR per CMS CMMI model (policy requirement)

    • Diagnosis of sickle cell disease as confirmed by genetic testing
    • Prescriber attests that the patient is clinically stable and fit for hematopoietic stem cell transplantation

    Exagamglogene autotemcel (Casgevy) - Reauthorization

    Exagamglogene autotemcel (Casgevy) - Reauthorization

    Reauthorization rules:

    ALL of the following

    • Casgevy is a one-time gene therapy and should not receive reauthorization unless the previous prior authorization has expired AND the patient did not receive the gene therapy

    Lovotibeglogene autotemcel (Lyfgenia) - Initial Therapy (Medical Necessity)

    Lovotibeglogene autotemcel (Lyfgenia) - Reauthorization

    Lovotibeglogene autotemcel (Lyfgenia) - Reauthorization

    Reauthorization rules:

    ALL of the following

    • Lyfgenia is a one-time gene therapy and should not receive reauthorization unless the previous prior authorization has expired AND the patient did not receive the gene therapy

    Applicable Codes

    HCPCS - gene therapy product codes (covered per treatment)HCPCSCovered
    J3392Injection, exagamglogene autotemcel, per treatment
    J3394Injection, lovotibeglogene autotemcel, per treatment

    Provider Actions and Billing Rules

    Prior Authorization

    Prior Authorization required for non-preferred agents and gene therapies

    Requests for Exagamglogene autotemcel (Casgevy) or Lovotibeglogene autotemcel (Lyfgenia) must meet the clinical criteria in this policy. New-to-market, non-preferred agents in this class are subject to prior authorization and require documentation of inadequate response or intolerance to preferred agents (two preferred agents, or one if only one preferred exists).

    • J3392
    • J3394
    Documentation Required

    Attestation and documentation requirements

    Provider attestation and documentation are required. The prescriber must attest the patient is clinically stable and fit for hematopoietic stem cell transplantation, provide genetic testing confirming a diagnosis of sickle cell disease, document prior use of hydroxyurea and that it resulted in treatment failure or is contraindicated or not tolerated, and document VOC/VOE frequency or chronic transfusion status based on provider attestation (see numeric thresholds for VOC/VOE in policy).

    Definitions

    Vaso-occlusive crises (VOC) / vaso-occlusive event (VOE): An episode of sickle cell disease exacerbation that may manifest as acute pain crises, acute chest syndrome, acute splenic sequestration, priapism, or splenic sequestration; diagnosed by a qualified medical professional within their scope of practice; and requires treatment at a medical facility (e.g., emergency department, hospital).

    Background

    Background: This policy addresses the use of recently available gene therapies that aim to replace the deficient gene responsible for producing hemoglobin in sickle cell disease, enabling production of normal, functioning hemoglobin.

    Apple Health participation: Apple Health participates in the CMS CMMI Cell and Gene Therapy Access Model. Under this model, treatment centers that provide gene therapies for sickle cell disease must be members of the CMS Designated Registry through CIBMTR and must be enrolled in CIBMTR before administering gene therapies to Apple Health clients.

    Policy metadata
    Policy number82.80.40-1
    Effective date2026-01-01
    Last review2025-11-19
    StatusCURRENT
    SubjectHematopoietic cell and gene therapies for sickle cell disease (Exagamglogene autotemcel Casgevy; Lovotibeglogene autotemcel Lyfgenia)

    Clinical Evidence

    Evidence: No structured evidence entries are included in the brief. Populate clinical trial identifiers, study summaries, and outcome metrics (e.g., VOC/VOE reduction, transfusion independence, survival, treatment-related adverse events) here if available.

    Revision History

    2026-01-01policy createdLatest

    Policy created and approved by HCA; New policy created

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyHematopoietic Agents – Sickle Cell Disease Cell and Gene Therapies
    Policy CodePolicy 82.80.40-1
    Change TypeNew policy created
    Effective DateJan 1, 2026
    Last ReviewNov 19, 2025
    Next Review DateN/A
    Key ActionRequests for Exagamglogene autotemcel or Lovotibeglogene autotemcel must meet the clinical criteria and non-preferred new-to-market agents are subject to prior authorization requiring inadequate response/intolerance to preferred agents.
    SourceLink
    On This Page
    Coverage SummaryExagamglogene autotemcel (Casgevy) - Initial Therapy (Medical Necessity)Exagamglogene autotemcel (Casgevy) - ReauthorizationLovotibeglogene autotemcel (Lyfgenia) - Initial Therapy (Medical Necessity)Lovotibeglogene autotemcel (Lyfgenia) - ReauthorizationApplicable CodesProvider Actions and Billing RulesDefinitionsBackgroundClinical EvidenceRevision History
    Patient is not a prior recipient of gene therapy or an allogenic hematopoietic stem cell transplant
  1. Patient has prior use of hydroxyurea and, per health care professional judgment, hydroxyurea resulted in treatment failure, is contraindicated, or patient is intolerant
  2. ONE of the following (evidence of recurrent VOCs)

    • Patient has experienced recurrent VOCs, defined as greater than or equal to two (2) documented VOCs per year in the previous twenty-four (24) months, based on provider attestation
    • Patient is currently receiving chronic transfusion therapy for recurrent VOCs, based on provider attestation
    • Age: patient ≥ 12 years at expected time of gene therapy administration
    • Hydroxyurea: prior use with treatment failure, contraindication, or intolerance (provider attestation)
    • VOC threshold for Casgevy: ≥ 2 documented VOCs per year in the prior 24 months (provider attestation)
    • VOE threshold for Lyfgenia: ≥ 4 VOEs requiring medical treatment in the prior 24 months (provider attestation)
    • Or current chronic transfusion therapy for recurrent VOCs/VOEs (provider attestation)
    Documentation Required

    Qualified treatment center and registry enrollment

    Treatment centers administering gene therapies for Apple Health clients must be enrolled in the Center for International Blood and Marrow Transplant Research (CIBMTR) and be members of the CMS Designated Registry as required under the CMS CMMI Cell and Gene Therapy Access Model.

    • Apple Health participates in the CMS CMMI Cell and Gene Therapy Access Model; participating centers must be enrolled in CIBMTR and be CMS Designated Registry members prior to administration.
    Billing Rule

    One-time therapy billing constraint

    Both Casgevy (Exagamglogene autotemcel) and Lyfgenia (Lovotibeglogene autotemcel) are single, one-time gene therapy doses. Reauthorization is not appropriate unless a prior authorization has expired and the patient did not receive the therapy.

    • J3392
    • J3394
    Scope summaryDefines medical necessity criteria, dosing/quantity limits, coding, and authorization rules for the two one-time gene therapies (Casgevy and Lyfgenia) for sickle cell disease with recurrent vaso-occlusive crises/events for Apple Health; requires treatment centers to be CIBMTR-enrolled per CMS CMMI model.